Please try another search
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Shinichi Suzukawa | 68 | 2019 | Head of Administrative Dept, Executive Officer & Director |
Shinji Hagiwara | 58 | 2022 | Executive Officer, Head of R&D Dept., Head of Business Development Dept. and Director |
Tatsuhiko Kodama | - | - | Member of Scientific Advisory Board |
Toshiya Tanaka | - | - | Member of Scientific Advisory Board |
Kinichiro Kominami | 57 | 2018 | Independent Outside Director |
Takuya Yokokawa | 64 | 2018 | President, CEO, Executive Officer & Chairman |
Tadashi Horiuchi | 78 | 2019 | Independent Outside Director |
Nobuo Hanai | 71 | 2021 | Independent Outside Director |
Takashi Ohno | 55 | 2021 | Independent Outside Director |
Tatsuya Nagase | 68 | 2022 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review